IL-6 Aptamer Binding Specificity for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for inflammatory, malignant, and autoimmune diseases that involve interleukin-6 (IL-6) are not effective for all patients, highlighting a need for alternative cytokine-targeting strategies.
Innovation Solution
Development of aptamers that specifically bind to IL-6, interfering with its signaling pathways and receptor binding, thereby inhibiting IL-6-mediated inflammatory and proliferative processes, which are administered alone or in combination with other active agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF-α agents are used to treat inflammatory diseases, then inflammation is reduced, but they are not effective in all patients
Solution Approach 1:
The patent shifts the therapeutic parameter from targeting TNF-α to targeting IL-6, a different cytokine in the inflammatory pathway. This parameter change allows treatment of patients who do not respond to anti-TNF-α agents, thereby improving broad applicability while maintaining therapeutic effectiveness through alternative mechanism of action
Solution Approach 2:
The IL-6 aptamer is designed to block multiple IL-6 signaling pathways (both classic and trans-signaling) simultaneously, providing universal inhibition of IL-6-mediated inflammation. This multi-functional approach ensures broad effectiveness across different inflammatory conditions and patient populations
2Reliability
If tocilizumab (anti-IL-6R antibody) is used to treat rheumatoid arthritis, then IL-6 signaling is blocked, but it requires intravenous administration and has limited tissue penetration
Solution Approach 1:
The patent replaces the large antibody molecule (tocilizumab) with a smaller aptamer molecule that can be delivered via different routes (including oral or topical). This substitution of the binding agent's physical properties improves ease of administration and enables better tissue penetration while maintaining IL-6 signaling inhibition
Solution Approach 2:
The invention changes the molecular size and structure parameter from antibody to aptamer, which fundamentally alters pharmacokinetic properties including administration route options and tissue distribution, thereby improving ease of operation
3Reliability
If aptamers with modified nucleotides are used to bind IL-6, then binding affinity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent introduces modified nucleotides only at specific local positions within the aptamer sequence where they provide maximum binding affinity improvement, rather than modifying the entire molecule. This localized modification approach maintains manufacturing relative simplicity while achieving high binding affinity to IL-6
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL-6 aptamers effectively prevent, treat, and ameliorate a wide range of diseases mediated by IL-6, including inflammatory diseases, cancers, and autoimmune conditions, by reducing IL-6 receptor binding and downstream signaling, offering a novel therapeutic approach beyond existing cytokine inhibitors.
Implementation Method 1
Aptamers are oligonucleotides that bind their targets with high affinity and specificity
Data Source
Figure 1~3
Figure 4~5
Figure 6~7
AI summary
Aptamers that bind IL-6 are provided. Pharmaceutical compositions comprising IL-6 aptamers are provided, as well as methods of treating conditions using the aptamers are also provided.